Despite a substantial downgrade in consensus revenue growth forecasts and a significantly higher future P/E multiple, the consensus analyst price target for Ginkgo Bioworks Holdings has increased from $7.95 to $8.67.
What's in the News
- Ginkgo Bioworks was selected by the U.S. DOE's Environmental Molecular Sciences Laboratory to deliver a $4.66M automated phenotyping platform, integrating advanced automation and AI-driven workflows.
- Launched a high-throughput, low-cost ADME profiling service through Ginkgo Datapoints, aimed at undercutting international vendors and accelerating small molecule drug development with AI-optimized datasets.
- Ginkgo's shares were added to numerous Russell indexes, including 2000, 2500, 3000, Microcap, and Small Cap completeness, both Growth and Value benchmarks, increasing its index representation.
- Steven Coen, Chief Accounting Officer, was named incoming CFO following the resignation of Mark Dmytruk.
- Ginkgo and Twist Bioscience updated their collaboration, granting Ginkgo preferential DNA pricing and allowing Twist to receive technology licenses while Ginkgo retains IP practice rights; both companies maintain strategic independence.
- Raised FY2025 total revenue guidance to $167–$187 million, up from the previous $160–$180 million range due to a $7 million non-cash deferred revenue release.
Valuation Changes
Summary of Valuation Changes for Ginkgo Bioworks Holdings
- The Consensus Analyst Price Target has risen from $7.95 to $8.67.
- The Consensus Revenue Growth forecasts for Ginkgo Bioworks Holdings has significantly fallen from -0.0% per annum to -12.5% per annum.
- The Future P/E for Ginkgo Bioworks Holdings has significantly risen from 31.43x to 56.87x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.